• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Inozyme Pharma Inc.

    4/29/25 4:31:36 PM ET
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INZY alert in real time by email
    DEFA14A 1 inzy_2025_defa14a_2025.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    (Rule 14a-101)

    INFORMATION REQUIRED IN PROXY STATEMENT

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

     

     

    ☐

     

    Preliminary Proxy Statement

     

     

    ☐

     

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

     

    ☐

     

    Definitive Proxy Statement

     

     

    ☒

     

    Definitive Additional Materials

     

     

    ☐

     

    Soliciting Material Pursuant to §240.14a-12

    INOZYME PHARMA, INC.

    (Name of registrant as specified in its charter)

     

    Not applicable.

    (Name of person(s) filing proxy statement, if other than the registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

     

     

     

     

    ☒

     

    ☐

     

    No fee required.

     

    Fee paid previously with preliminary materials.

    ☐

     

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     


     

    img248533281_0.jpg

     

    inozyme pharma Inozyme Pharma, Inc. Important Notice Regarding the Availability of Proxy Materials for the P.O. BOX 8016, CARY, NC 27512-9903 Stockholders Meeting to be held on June 25, 2025 For Stockholders of record as of April 28, 2025 This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. To view the proxy statement and annual report, and to register to attend the virtual annual meeting, go to: www.proxydocs.com/INZY To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. We have chosen to use these procedures for our annual meeting. For a convenient way to VIEW proxy materials and VOTE go to www.proxydocs.com/INZY Have the 12 digit control number located in the shaded box above available when you access the website and follow the instructions. Proxy Materials Available to View or Receive: Proxy Statement, Proxy Card and Annual Report If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before June 13, 2025. To order paper materials, use one of the following methods. INTERNET www.investorelections.com/INZY TELEPHONE (866) 648-8133 * E-MAIL [email protected] When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above. * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located above) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Inozyme Pharma, Inc. Meeting Type: Annual Meeting of Stockholders Date: Wednesday, June 25, 2025 Time: 9:15 AM, Eastern Time Place: Annual Meeting to be held live via Internet. Please visit www.proxydocs.com/INZY for more details. In order to attend the meeting online and to vote your shares electronically during the meeting, you must register in advance at www.proxydocs.com/INZY prior to the registration deadline of June 23, 2025 at 5:00 PM, Eastern Time. SEE REVERSE FOR FULL AGENDA


     

    img248533281_1.jpg

     

    Inozyme Pharma, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR EACH OF THE NOMINEES IN PROPOSAL 1 AND FOR PROPOSAL 2. PROPOSAL The election of three Class II directors, Sarah Bhagat, Reinaldo Diaz and Erik Harris, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders. 1.01 Sarah Bhagat 1 2 1.02 Reinaldo Diaz 1.03 Erik Harris The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. Note: The proxies are authorized to vote, in their discretion, upon such other business that may properly come before the Annual Meeting or any adjournment or postponement thereof.


    Get the next $INZY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INZY

    DatePrice TargetRatingAnalyst
    12/12/2024$26.00Outperform
    Raymond James
    9/12/2024$16.00Buy
    Stifel
    8/13/2024$16.00 → $17.00Buy
    Jefferies
    5/30/2024$14.00Overweight
    Wells Fargo
    3/23/2023$4.50 → $6.00Hold → Buy
    Jefferies
    5/26/2022$5.00Hold
    Jefferies
    2/7/2022$33.00Buy
    HC Wainwright & Co.
    11/29/2021$23.00Buy
    Needham
    More analyst ratings

    $INZY
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Inozyme Pharma Inc.

    SCHEDULE 13G/A - Inozyme Pharma, Inc. (0001693011) (Subject)

    7/17/25 7:54:39 PM ET
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 15-12G filed by Inozyme Pharma Inc.

    15-12G - Inozyme Pharma, Inc. (0001693011) (Filer)

    7/11/25 6:02:23 AM ET
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Inozyme Pharma Inc.

    EFFECT - Inozyme Pharma, Inc. (0001693011) (Filer)

    7/2/25 12:15:26 AM ET
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INZY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, CFO & Head of BD Subramanian Sanjay closing all direct ownership in the company (SEC Form 4)

    4 - Inozyme Pharma, Inc. (0001693011) (Issuer)

    7/3/25 7:16:07 PM ET
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    COO Winton Matthew closing all direct ownership in the company (SEC Form 4)

    4 - Inozyme Pharma, Inc. (0001693011) (Issuer)

    7/3/25 7:08:49 PM ET
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bolte Axel closing all direct ownership in the company (SEC Form 4)

    4 - Inozyme Pharma, Inc. (0001693011) (Issuer)

    7/3/25 7:07:07 PM ET
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INZY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioMarin Announces Completion of Acquisition of Inozyme

    SAN RAFAEL, Calif., July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (NASDAQ:INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million. The acquisition will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701. The medicine is currently being developed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones. On May 16, 2025, BioMarin and Inozyme announced tha

    7/1/25 8:45:00 AM ET
    $BMRN
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

    BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) today announced that it has postponed its 2025 Annual Meeting of Stockholders (the "Annual Meeting"), which was scheduled to be held on June 25, 2025, in light of the previously announced acquisition (the "Acquisition") by BioMarin Pharmaceutical Inc. ("BioMarin"). If the Acquisition is completed, there will be no Annual Meeting involving public stockholders. If the Acquisition is not completed, the Board of Directors will take such further action as it deems appropriate to call and convene the Annual Meeting at a later date, including the establishment of a new record date for determining the stockholders entitl

    6/20/25 5:00:00 PM ET
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

    Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages  Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m. ET SAN RAFAEL, Calif. and BOSTON, May 16, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Inozyme Pharma, Inc. (NASDAQ:INZY) announced today that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share in an all-cash transa

    5/16/25 7:30:00 AM ET
    $BMRN
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INZY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on Inozyme Pharma with a new price target

    Raymond James initiated coverage of Inozyme Pharma with a rating of Outperform and set a new price target of $26.00

    12/12/24 8:10:19 AM ET
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Inozyme Pharma with a new price target

    Stifel initiated coverage of Inozyme Pharma with a rating of Buy and set a new price target of $16.00

    9/12/24 7:42:17 AM ET
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Inozyme Pharma with a new price target

    Jefferies resumed coverage of Inozyme Pharma with a rating of Buy and set a new price target of $17.00 from $16.00 previously

    8/13/24 7:33:31 AM ET
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INZY
    Financials

    Live finance-specific insights

    View All

    BioMarin Announces Completion of Acquisition of Inozyme

    SAN RAFAEL, Calif., July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (NASDAQ:INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million. The acquisition will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701. The medicine is currently being developed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones. On May 16, 2025, BioMarin and Inozyme announced tha

    7/1/25 8:45:00 AM ET
    $BMRN
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

    Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages  Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m. ET SAN RAFAEL, Calif. and BOSTON, May 16, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Inozyme Pharma, Inc. (NASDAQ:INZY) announced today that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share in an all-cash transa

    5/16/25 7:30:00 AM ET
    $BMRN
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

    - Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) - - Natural history study highlights stroke as common feature among patients with early-onset ABCC6 Deficiency - - Favorable safety, immunogenicity and clinical outcome data were maintained through 48 weeks in Cohorts 1-3 in ENPP1 Deficiency; Data from Cohort 4 support once weekly dosing in ongoing and future clinical trials - - Company to host conference call and webcast today at 8:00 a.m. ET - BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage

    4/8/24 6:30:35 AM ET
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INZY
    Leadership Updates

    Live Leadership Updates

    View All

    Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights

    - Interim data from ENERGY 3 trial highlight INZ-701's potential to modify disease course in ENPP1 Deficiency, with sustained phosphate increases and favorable safety and immunogenicity profile to date - - ENERGY 3 trial on track for topline data in first quarter of 2026; no patient dropouts, dose adjustments or discontinuations, and no new safety signals - - Petra Duda, M.D., Ph.D. appointed Chief Medical Officer - BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today reported financi

    5/14/25 7:30:00 AM ET
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights

    - Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Topline data from ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, expected in early 2026 - - Company plans to initiate registrational trials in calciphylaxis and ABCC6 Deficiency in 2025 subject to regulatory alignment and sufficient funding - - Cash, cash equivalents, and short-term investments as of September 30, 2024, expected to fund operations into the fourth quarter of 2025 – BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical c

    11/5/24 8:30:00 AM ET
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors

    BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced the appointment of Erik Harris to its Board of Directors, effective October 3, 2024. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings to Inozyme over 20 years of commercial expertise within the biopharma industry. "It is a privilege to welcome Erik to the Inozyme Board of Directors at this exciting juncture for Inozyme as we continue to lay the groundwork for ou

    10/7/24 8:30:17 AM ET
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INZY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Inozyme Pharma Inc.

    SC 13G - Inozyme Pharma, Inc. (0001693011) (Subject)

    12/9/24 4:14:49 PM ET
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Inozyme Pharma Inc.

    SC 13G/A - Inozyme Pharma, Inc. (0001693011) (Subject)

    11/14/24 12:19:37 PM ET
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Inozyme Pharma Inc.

    SC 13G - Inozyme Pharma, Inc. (0001693011) (Subject)

    10/24/24 2:02:10 PM ET
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care